Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
67 hedge funds and large institutions have $42.1M invested in Zynerba Pharmaceuticals, Inc in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 10 closing their positions.
95% more capital invested
Capital invested by funds: $21.6M → $42.1M (+$20.5M)
90% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 10
73% more call options, than puts
Call options by funds: $4.74M | Put options by funds: $2.74M
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
16% more funds holding
Funds holding: 58 → 67 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$4.2M |
| 2 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
+$2.94M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.22M |
| 4 |
PCM
Penserra Capital Management
Orinda,
California
|
+$1.03M |
| 5 |
BlackRock
New York
|
+$857K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$1.61M |
| 2 |
Renaissance Technologies
New York
|
-$475K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$426K |
| 4 |
LSA
Leonteq Securities AG
Zurich,
Switzerland
|
-$322K |
| 5 |
SC
Sculptor Capital
New York
|
-$271K |
ZYNE Hedge Fund Activity: Q1 2021 in Review
67 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q1 2021, worth a combined $42.1M — up 95% from $21.6M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ZYNE positions and 10 closed out — a net gain of 9 holders — while 20 added to existing stakes and 12 trimmed.
The largest buyer was AdvisorShares Investments, adding an estimated $4.2M. The largest seller was Mirae Asset Global Investments, cutting an estimated $1.61M.
- 67 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q1 2021, up from 58 in Q4 2020.
- Funds reported $42.1M of Zynerba Pharmaceuticals, Inc stock for Q1 2021, up 95% quarter-over-quarter.
- 19 funds opened new Zynerba Pharmaceuticals, Inc positions in Q1 2021 and 10 closed out, a net change of +9 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q1 2021 was AdvisorShares Investments, an estimated $4.2M added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q1 2021 was Mirae Asset Global Investments, an estimated $1.61M sold.
Based on aggregated 13F filings for Q1 2021.